Name (Synonyms) | Correlation |
---|
There is one clinical trial.
High risk outpatient adult males with a confirmed SARS-CoV-2 infection will be included in the study. Patients will be randomized to receive Enzalutamide with standard of care (SOC) or SOC alone. Enzalutamide will be administered daily p.o. from Day 1 to Day 28 or until confirmed negativization of Nasopharyngeal swap (NPS) Polymerase chain reaction (PCR) (2 consecutive negative samples), whichever occurs first.
Description: efficacy of Enzalutamide in decreasing the nasopharyngeal swap SARS-CoV-2 viral load until negativization
Measure: Efficacy of Enzalutamide Time: 28 daysDescription: Efficacy of Enzalutamide in controlling disease progression of SARS-CoV-2 viral load
Measure: Disease progression Time: 28 daysDescription: Evaluation of Enzalutamide tolerability in terms of incidence and severity grade of side effects
Measure: Tollerability of Enzalutamide Time: 28 days